JPWO2021044005A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021044005A5 JPWO2021044005A5 JP2022514681A JP2022514681A JPWO2021044005A5 JP WO2021044005 A5 JPWO2021044005 A5 JP WO2021044005A5 JP 2022514681 A JP2022514681 A JP 2022514681A JP 2022514681 A JP2022514681 A JP 2022514681A JP WO2021044005 A5 JPWO2021044005 A5 JP WO2021044005A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- seq
- binding portion
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 23
- 102000036639 antigens Human genes 0.000 claims 23
- 108091007433 antigens Proteins 0.000 claims 23
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 18
- 102100022464 5'-nucleotidase Human genes 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 238000000338 in vitro Methods 0.000 claims 12
- 230000002401 inhibitory effect Effects 0.000 claims 11
- 230000000694 effects Effects 0.000 claims 10
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 230000006052 T cell proliferation Effects 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000011577 humanized mouse model Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 3
- 230000004614 tumor growth Effects 0.000 claims 3
- 241000282567 Macaca fascicularis Species 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 229960001438 immunostimulant agent Drugs 0.000 claims 2
- 239000003022 immunostimulating agent Substances 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 230000003844 B-cell-activation Effects 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 238000011789 NOD SCID mouse Methods 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 201000007180 bile duct carcinoma Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 210000000777 hematopoietic system Anatomy 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 102000045309 human NT5E Human genes 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962896908P | 2019-09-06 | 2019-09-06 | |
| US62/896,908 | 2019-09-06 | ||
| PCT/EP2020/074804 WO2021044005A1 (en) | 2019-09-06 | 2020-09-04 | Anti-cd73 antibodies |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022547081A JP2022547081A (ja) | 2022-11-10 |
| JP2022547081A5 JP2022547081A5 (https=) | 2023-09-08 |
| JPWO2021044005A5 true JPWO2021044005A5 (https=) | 2023-09-08 |
| JP7662617B2 JP7662617B2 (ja) | 2025-04-15 |
Family
ID=72517218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514681A Active JP7662617B2 (ja) | 2019-09-06 | 2020-09-04 | 抗ｃｄ７３抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11634500B2 (https=) |
| EP (1) | EP4025605A1 (https=) |
| JP (1) | JP7662617B2 (https=) |
| KR (1) | KR20220057558A (https=) |
| CN (1) | CN115023439B (https=) |
| AU (1) | AU2020342778A1 (https=) |
| BR (1) | BR112022003956A2 (https=) |
| CA (1) | CA3153213A1 (https=) |
| CL (1) | CL2024002093A1 (https=) |
| CO (1) | CO2022002622A2 (https=) |
| IL (1) | IL291068A (https=) |
| MX (1) | MX2022002682A (https=) |
| MY (1) | MY207784A (https=) |
| PE (1) | PE20220708A1 (https=) |
| PH (1) | PH12022550509A1 (https=) |
| TW (1) | TWI859319B (https=) |
| UA (1) | UA130408C2 (https=) |
| WO (1) | WO2021044005A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021138467A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Anti-cd73 antibodies and uses thereof |
| CA3166536A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy |
| CN115734972A (zh) * | 2020-06-22 | 2023-03-03 | 信达生物制药(苏州)有限公司 | 抗cd73抗体及其用途 |
| GB202105110D0 (en) * | 2021-04-09 | 2021-05-26 | Cancer Research Tech Ltd | Anti-CD73 antibodies |
| CN119173276A (zh) | 2022-04-13 | 2024-12-20 | 吉利德科学公司 | 用于治疗表达Trop-2的癌症的组合疗法 |
| CN117304316A (zh) * | 2022-06-22 | 2023-12-29 | 复旦大学 | 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN116178546B (zh) * | 2022-10-13 | 2024-06-18 | 深圳市百士通科技开发有限公司 | 一种多功能重组抗体及其制备方法和应用 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025135233A1 (ko) * | 2023-12-21 | 2025-06-26 | ㈜지아이이노베이션 | Cd73에 특이적으로 결합하는 항체 및 이의 용도 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US338841A (en) | 1886-03-30 | herden | ||
| US256055A (en) | 1882-04-04 | Compound engine | ||
| US323997A (en) | 1885-08-11 | Machine-gun | ||
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| AU584417B2 (en) | 1985-04-01 | 1989-05-25 | Lonza Group Ag | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| MXPA01011279A (es) | 1999-05-07 | 2002-07-02 | Genentech Inc | Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b. |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| AU5914201A (en) | 2000-04-25 | 2001-11-07 | Idec Pharma Corp | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
| WO2004079013A1 (en) | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
| EP2062916A3 (en) | 2003-04-09 | 2009-08-19 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor |
| WO2006113181A2 (en) | 2005-04-08 | 2006-10-26 | University Of Florida Research Foundation, Inc. | Stem-like cells in bone sarcomas |
| BRPI0612947A2 (pt) | 2005-05-18 | 2010-12-07 | Biogen Idec Inc | método para o tratamento de uma condição fibrótica, método para tratar a fibrose pulmonar, método para tratar a fibrose hepática, método para tratar a fibrose renal, métodos para tratar uma doença fibrótica e método para prevenir uma doença fibrótica |
| WO2007062090A2 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
| US8975081B2 (en) | 2007-10-24 | 2015-03-10 | Faron Pharmaceuticals Oy | Biomarker for monitoring development of diseases and assessing the efficacy of therapies |
| US20130331297A1 (en) * | 2010-07-16 | 2013-12-12 | Avantgen, Inc. | Novel peptides and uses thereof |
| WO2014153424A1 (en) | 2013-03-19 | 2014-09-25 | La Jolla Institute For Allergy And Immunology | Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins) |
| US10059761B2 (en) * | 2014-03-12 | 2018-08-28 | Prothena Biosciences Limited | Anti-Laminin4 antibodies specific for LG4-5 |
| IL250579B2 (en) | 2014-10-10 | 2023-05-01 | Innate Pharma | blocking cd73 |
| US20180030144A1 (en) | 2014-10-10 | 2018-02-01 | Innate Pharma | Cd73 blockade |
| DK3218406T4 (da) | 2014-11-10 | 2024-12-09 | Medimmune Ltd | Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf |
| EP3218407A1 (en) | 2014-11-11 | 2017-09-20 | Medimmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
| MY189836A (en) * | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| CA2988119A1 (en) | 2015-06-03 | 2016-12-08 | Dana-Farber Cancer Institute, Inc. | Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy |
| JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| PL3368572T3 (pl) * | 2015-10-02 | 2022-09-12 | Symphogen A/S | Przeciwciała anty-PD-1 oraz kompozycje |
| US11130817B2 (en) | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
| WO2017100670A1 (en) | 2015-12-09 | 2017-06-15 | Corvus Pharmaceuticals, Inc. | Humanized anti-cd73 antibodies |
| WO2017167921A1 (en) | 2016-03-30 | 2017-10-05 | Centre Léon-Bérard | Lymphocytes expressing cd73 in cancerous patient dictates therapy |
| WO2018013611A1 (en) | 2016-07-11 | 2018-01-18 | Corvus Pharmaceuticals, Inc. | Anti-cd73 antibodies |
| MY194596A (en) * | 2016-09-23 | 2022-12-06 | Regeneron Pharma | Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates |
| MY203971A (en) * | 2016-10-13 | 2024-07-26 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Anti-lag-3 antibodies and compositions |
| EP3383916B1 (en) | 2017-01-24 | 2022-02-23 | I-Mab Biopharma US Limited | Anti-cd73 antibodies and uses thereof |
| WO2018187512A1 (en) | 2017-04-04 | 2018-10-11 | Corvus Pharmaceuticals, Inc. | Methods for treating cd73hi tumors |
| WO2018215535A1 (en) | 2017-05-23 | 2018-11-29 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel cd73 antibody, preparation and uses thereof |
| CN118307674A (zh) | 2017-06-22 | 2024-07-09 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| TWI823906B (zh) | 2018-03-09 | 2023-12-01 | 美商艾吉納斯公司 | 抗-cd73 抗體及其使用方法 |
-
2020
- 2020-09-04 US US17/012,942 patent/US11634500B2/en active Active
- 2020-09-04 PH PH1/2022/550509A patent/PH12022550509A1/en unknown
- 2020-09-04 AU AU2020342778A patent/AU2020342778A1/en active Pending
- 2020-09-04 MY MYPI2022001106A patent/MY207784A/en unknown
- 2020-09-04 JP JP2022514681A patent/JP7662617B2/ja active Active
- 2020-09-04 EP EP20772002.0A patent/EP4025605A1/en active Pending
- 2020-09-04 MX MX2022002682A patent/MX2022002682A/es unknown
- 2020-09-04 WO PCT/EP2020/074804 patent/WO2021044005A1/en not_active Ceased
- 2020-09-04 BR BR112022003956A patent/BR112022003956A2/pt unknown
- 2020-09-04 UA UAA202201023A patent/UA130408C2/uk unknown
- 2020-09-04 PE PE2022000364A patent/PE20220708A1/es unknown
- 2020-09-04 KR KR1020227010511A patent/KR20220057558A/ko active Pending
- 2020-09-04 TW TW109130508A patent/TWI859319B/zh active
- 2020-09-04 CN CN202080076881.9A patent/CN115023439B/zh active Active
- 2020-09-04 CA CA3153213A patent/CA3153213A1/en active Pending
-
2022
- 2022-03-02 IL IL291068A patent/IL291068A/en unknown
- 2022-03-04 CO CONC2022/0002622A patent/CO2022002622A2/es unknown
-
2023
- 2023-03-17 US US18/185,848 patent/US20230227573A1/en active Pending
-
2024
- 2024-07-10 CL CL2024002093A patent/CL2024002093A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111936164B (zh) | 癌的治疗和/或预防用药物组合物 | |
| Mendelsohn | Blockade of receptors for growth factors: an anticancer therapy—the fourth annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture | |
| JP7316120B2 (ja) | 腫瘍性疾患のための治療 | |
| JPWO2021044005A5 (https=) | ||
| JP4854912B2 (ja) | 癌に対する抗体 | |
| JP7797875B2 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| TWI817190B (zh) | 抗ｃ-Ｍｅｔ抗體藥物偶聯物及其應用 | |
| JP2002515511A (ja) | 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療 | |
| RU2007133108A (ru) | АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ | |
| CN116615250A (zh) | 通过施用抗b7-h3抗体-药物缀合物的间皮瘤治疗 | |
| CN114761433B (zh) | 一种抗Claudin18.2单克隆抗体、其制备方法及用途 | |
| WO2016131409A1 (zh) | 抗体药物偶联物 | |
| JPWO2023288241A5 (https=) | ||
| Mendelsohn | Jeremiah Metzger Lecture. Targeted cancer therapy | |
| JP7715041B2 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| KR20240012472A (ko) | 요로상피암 치료에 있어서 면역관문 억제제와 병용투여되는 항체-약물 접합체의 용도 | |
| WO2021182570A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| WO2021182574A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| JPWO2021209495A5 (https=) | ||
| NZ785824B2 (en) | Anti-cd73 antibodies | |
| NZ785824A (en) | Anti-cd73 antibodies | |
| EP4681780A1 (en) | Immunocytokine for cancer treatment | |
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
| WO2016163433A1 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 | |
| JPWO2021173832A5 (https=) |